TLRY: Tilray, Inc. prior to merger with Aphria Inc. - Summary | Jitta

Tilray, Inc. prior to merger with Aphria Inc.

NASDAQ:TLRY

Price
$17.02
Loss Chance
57.3%
1.61JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
344 / 981
2,822 / 4,423
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (46)
Recent Business Performance (61)
Financial Strength (21)
Return to Shareholders (0)
Competitive Advantage (43)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Recent IPOLess than 3 years
Operating MarginInconsistent
Recent Business PerformanceEarning decline 14.16% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.61
100.00%
2.09
225.25%
2.30
237.17%
Pharmaceuticals
5.45
1.15%
3.78
83.51%
4.61
46.42%
COMPANY DESCRIPTION
As per the transaction announced on October 12, 2020, Tilray, Inc. prior to merger with Aphria Inc. was acquired by Tilray, Inc., in a reverse merger transaction. Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, clinics, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, Germany, Israel, New Zealand, Portugal, Spain, Africa, Switzerland, the United States, Malta, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.